### Abstract

We report on the chromosomal pattern of 120 patients with childhood AML de novo. One hundred and fifteen patients (96%) had adequate samples for analysis; 98 (85%) of these showed clonal karyotypic abnormalities. They were classified into cytogenetic subgroups which were closely correlated with FAB subtypes: t(8;21) and M2 (n = 9); t(15;17) and M3 (n = 12); inv(16) and M4Eo (n = 9); t(9;11) and M5a (n = 10); t(11q23) other than t(9;11) and M4-M5 (n = 11); and t(1;22) and M7 (n = 4), In patients with -7/del(7q)(n = 6), leukemia was preceded by MDS in half of the cases, although they had diverse FAB subtypes. Thirty-seven patients had miscellaneous abnormalities. Despite a high CR rate, patients with t(8;21) had a very poor survival: only one child was event-free at 3 years from diagnosis. One third of patients with t(15;17) died during induction. Those eight who achieved CR fared well: only two relapsed, and six were event-free survivors. Patients with inv(16) had a high remission rate and a long survival: five children were in CR 20 to 136 months. Both groups with t(9;11) and t(11q23) had a high remission rate: however, outcome was superior for the t(9;11) group when compared to either the t(11q23) group (EFS at 3 years ± SE, 56+ ± 17% vs. 11 ± 10%, p = 0.07) or to the remaining patients (p = 0.06). Both -7/del(7q) and t(1;22) groups had low CR rates (50%) and poor survival. Cytogenetic analysis identifies clinically distinct subsets of childhood AML and is useful in tailoring treatment for these patients. Favorable cytogenetic groups (t(15;17), inv(16), and t(9;11)) may do well with current therapy protocols, whereas unfavorable groups (t(11q23), t(8;21), -7/del(7q), and t(1;22)) require more effective therapies.

Original language | English (US) |
---|---|

Pages (from-to) | 95-101 |

Number of pages | 7 |

Journal | Leukemia |

Volume | 9 |

Issue number | 1 |

State | Published - Jan 1 1995 |

### Fingerprint

### Keywords

- Acute myeloid leukemia
- Karyotype in childhood leukemia
- Prognostic significance

### ASJC Scopus subject areas

- Hematology
- Cancer Research
- Anesthesiology and Pain Medicine

### Cite this

*Leukemia*,

*9*(1), 95-101.

}

*Leukemia*, vol. 9, no. 1, pp. 95-101.

**Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo.** / Martinez-Climent, J. A.; Lane, N. J.; Rubin, C. M.; Morgan, E.; Johnstone, H. S.; Mick, R.; Murphy, S. B.; Vardiman, J. W.; Larson, R. A.; Le Beau, M. M.; Rowley, J. D.

Research output: Contribution to journal › Article

TY - JOUR

T1 - Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo

AU - Martinez-Climent, J. A.

AU - Lane, N. J.

AU - Rubin, C. M.

AU - Morgan, E.

AU - Johnstone, H. S.

AU - Mick, R.

AU - Murphy, S. B.

AU - Vardiman, J. W.

AU - Larson, R. A.

AU - Le Beau, M. M.

AU - Rowley, J. D.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - We report on the chromosomal pattern of 120 patients with childhood AML de novo. One hundred and fifteen patients (96%) had adequate samples for analysis; 98 (85%) of these showed clonal karyotypic abnormalities. They were classified into cytogenetic subgroups which were closely correlated with FAB subtypes: t(8;21) and M2 (n = 9); t(15;17) and M3 (n = 12); inv(16) and M4Eo (n = 9); t(9;11) and M5a (n = 10); t(11q23) other than t(9;11) and M4-M5 (n = 11); and t(1;22) and M7 (n = 4), In patients with -7/del(7q)(n = 6), leukemia was preceded by MDS in half of the cases, although they had diverse FAB subtypes. Thirty-seven patients had miscellaneous abnormalities. Despite a high CR rate, patients with t(8;21) had a very poor survival: only one child was event-free at 3 years from diagnosis. One third of patients with t(15;17) died during induction. Those eight who achieved CR fared well: only two relapsed, and six were event-free survivors. Patients with inv(16) had a high remission rate and a long survival: five children were in CR 20 to 136 months. Both groups with t(9;11) and t(11q23) had a high remission rate: however, outcome was superior for the t(9;11) group when compared to either the t(11q23) group (EFS at 3 years ± SE, 56+ ± 17% vs. 11 ± 10%, p = 0.07) or to the remaining patients (p = 0.06). Both -7/del(7q) and t(1;22) groups had low CR rates (50%) and poor survival. Cytogenetic analysis identifies clinically distinct subsets of childhood AML and is useful in tailoring treatment for these patients. Favorable cytogenetic groups (t(15;17), inv(16), and t(9;11)) may do well with current therapy protocols, whereas unfavorable groups (t(11q23), t(8;21), -7/del(7q), and t(1;22)) require more effective therapies.

AB - We report on the chromosomal pattern of 120 patients with childhood AML de novo. One hundred and fifteen patients (96%) had adequate samples for analysis; 98 (85%) of these showed clonal karyotypic abnormalities. They were classified into cytogenetic subgroups which were closely correlated with FAB subtypes: t(8;21) and M2 (n = 9); t(15;17) and M3 (n = 12); inv(16) and M4Eo (n = 9); t(9;11) and M5a (n = 10); t(11q23) other than t(9;11) and M4-M5 (n = 11); and t(1;22) and M7 (n = 4), In patients with -7/del(7q)(n = 6), leukemia was preceded by MDS in half of the cases, although they had diverse FAB subtypes. Thirty-seven patients had miscellaneous abnormalities. Despite a high CR rate, patients with t(8;21) had a very poor survival: only one child was event-free at 3 years from diagnosis. One third of patients with t(15;17) died during induction. Those eight who achieved CR fared well: only two relapsed, and six were event-free survivors. Patients with inv(16) had a high remission rate and a long survival: five children were in CR 20 to 136 months. Both groups with t(9;11) and t(11q23) had a high remission rate: however, outcome was superior for the t(9;11) group when compared to either the t(11q23) group (EFS at 3 years ± SE, 56+ ± 17% vs. 11 ± 10%, p = 0.07) or to the remaining patients (p = 0.06). Both -7/del(7q) and t(1;22) groups had low CR rates (50%) and poor survival. Cytogenetic analysis identifies clinically distinct subsets of childhood AML and is useful in tailoring treatment for these patients. Favorable cytogenetic groups (t(15;17), inv(16), and t(9;11)) may do well with current therapy protocols, whereas unfavorable groups (t(11q23), t(8;21), -7/del(7q), and t(1;22)) require more effective therapies.

KW - Acute myeloid leukemia

KW - Karyotype in childhood leukemia

KW - Prognostic significance

UR - http://www.scopus.com/inward/record.url?scp=0028918255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028918255&partnerID=8YFLogxK

M3 - Article

C2 - 7845034

AN - SCOPUS:0028918255

VL - 9

SP - 95

EP - 101

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 1

ER -